Ardelyx: IBSRELA Momentum Drives Opportunity

Ardelyx ( ARDX ) has developed into a commercial execution machine with two FDA-approved, first-in-class medications. Coming into 2026, Ardelyx has a dual-franchise model, which will allow for strong revenue growth while providing a diversified revenue floor. Historically, the nephrology space hasI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinkin ...